Amrinone, forerunner of novel cardiotonic agents, caused paradigm shift of heart failure pharmacotherapy

Circ Res. 2013 Aug 2;113(4):358-61. doi: 10.1161/CIRCRESAHA.113.301689.

Author

Affiliation

¹ Department of Pharmacology, Yamagata University School of Medicine, Yamagata, Japan. mendou@med.id.yamagata-u.ac.jp

PMID: 23908328
DOI: 10.1161/CIRCRESAHA.113.301689

No abstract available

MeSH terms

Amrinone / pharmacology
Amrinone / therapeutic use*
Animals
Calcium Signaling / physiology
Cardiotonic Agents / pharmacology
Cardiotonic Agents / therapeutic use*
Chronic Disease
Disease Models, Animal
Dogs
Drug Therapy / trends*
Heart Failure / drug therapy*
Heart Failure / physiopathology
Phosphodiesterase 3 Inhibitors / pharmacology
Phosphodiesterase 3 Inhibitors / therapeutic use
Vasodilation / drug effects
Vasodilation / physiology

Substances

Cardiotonic Agents
Phosphodiesterase 3 Inhibitors
Amrinone